Sacubitril/valsartan (ARNI) is getting more attention in the guidelines with regards to its use in heart failure (specifically HFrEF). Many patients are already on an ACE and making the transition from an ACE inhibitor to an ARNI is likely something you will come...
Akathisia is one of the most common symptoms associated with extrapyramidal symptoms (EPS) due to antipsychotics. There are a few different medications that we can use for the management of akathisia. Here’s a good summary of akathisia. Prior to even considering...
I don’t see bromocriptine used very often in clinical practice, but as a pharmacist, I feel the need to know every medication I come across. Here’s a list of my top bromocriptine clinical pearls! I think one of the most important things to recognize is...
Obesity is a major risk factor for many comorbidities (hypertension, dyslipidemia, osteoarthritis, sleep apnea, heart disease, type 2 diabetes) and increases all-cause and cardiovascular mortality. With over 40% of Americans qualifying as obese (body mass index ≥30...
A new treatment for chronic weight management is likely on the way. In a recent trial, investigators looked at semaglutide for weight loss. The final results of the STEP1 trial (Semaglutide Treatment Effect in People with obesity) were recently reported in the New...
Parkinson’s disease (PD) has long presented challenges in medication delivery. A staple in more advanced disease control, carbidopa-levodopa requires multiple daily dosing with supratherapeutic levels leading to dyskinesias and subtherapeutic concentrations leading to...
